Fibrinolysis can be used to increase fluid drainage in pleural infections. Treatment with urokinase or plasminogen activator Network (T-PA) in relation to DNASE through chest tubes has been effective in reducing the need for operation. This research is the first to compare the efficacy of both treatments. We conducted a single center cohort study study, controlled. All individuals with pleural infections were treated at our hospital between January 2014 and December 2017 which were treated with antibiotics, chest tubes and fibrinolysis included in this study. The level of additional procedure requirements (additional chest tube or operation) after initial fibrinolysis, complications, costs, and radiological and biological results are analyzed. Among 93 patients included in this study, 34% needed additional procedures after the initial fibrinolysis, including 21% who received additional chest tubes and 13% who underwent thoracoscopy.
The need for additional procedures arises due to several pleural collections (p = 0.01) and associated with the use of large drill drain (p = 0.01). The fibrinolysis success rate does not differ significantly between urokinase and T-PA / DNase (p = 0.35). The difference in the duration of drainage and the length of stay in the hospital is also insignificant (p = 0.05 and p = 0.12, respectively). Treatment with T-PA / DNase is cheaper (p = 0.04) but is associated with a higher Haemothorax level (p = 0.002). In conclusion, treatment with urokinase is safer and equally effective when compared to treatment with T-PA / DNASE.
Both cell lines continue to multiply with prolonged treatment and show an increase in the activity of the urokinase plasminogen activity. Analysis of gene expression and cell phenotypes reveal different mechanisms, which are only in cell neuroblastoma H4 can show the process of transitional-mesenchymal transitions. Data collected shows that the activity of the urokinase plasminogen activator, even though it has extracellular proteases, it does not need to lead to reprogramming the epithelial-mesenchymal and increased cell migration but can have different results depending on the intracellular environment.
Urokinase type plasminogen activator receptors are soluble as biomarker response treatment in childhood tuberculosis.
Children’s tuberculosis (TB) is a major health problem throughout the world, especially in developing countries. In 2015, it was estimated at 950,000 cases of childhood TB. Because most TB in children is Paucibacillary, this raises not only to diagnose but also in monitoring the response to anti-TB treatment as well. Plasminogen Plasminogen Activator Type Dissolved Urokinase (Soup), the membrane protein that glikilphosphosphatidylinocytolocyphatidylinositol from various immune system cells, is one of the potential biomarkers used in TB management. The purpose of this study was to study the decrease in serum service level after anti-TB treatment in children with TB and its relationship with the characteristics of the patient.
We conducted a prospective study of children suspected of having TB because of contact history with active TB with active TB cases and symptoms such as cough, fever, and enlarged lymph nodes. TB diagnosis was established by history, physical examination including anthropometric examination. TUKU Tuberculin uses PPD RT-23 and the release test of interferon-gamma with quantiferon TB-Gold Plus is done. TNFα mediated MMP-9 expression in the THP-1 monocy that was induced by urokinase (UPA). UPREGULATION MMP-9 caused by UPA and TNFα is pressed by ethanercept, TNFα inhibitors. In addition, the upa stimulates the expression of MRNA TNFα.
Both the upa and TNFα induces the ROS generation in a monocyte, while the MMP-9 secretion is induced by UPA and TNFα is inhibited by antioxidants. NFKB Inhibitors, PPARα and PPARγ receptor ligands, and SIRT1 activators negatively affect MMP-9 secretion caused by UPA.
Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection.
Kinetics from late urokinase plasminogen activator receptors (Supar) in cirrhosis.
The late urokinase plastinogenic activator receptor is related to liver and fibrosis inflammation and has been advised to participate in the development of liver cirrhosis. Therefore, the purpose of this study was to measure the concentration of supar on the hitch-hematical veins of cirrhosis during the liver vein catheterization to identify the possibility of the generation of hepatic Super. Next, we explore if flaring levels are associated with cirrhosis and liver dysfunction. We involved 105 cirrhotic patients and 19 healthy controls. Blood is covered from the liver veins and femoral arteries and supar are measured by Immunosorben assay associated with artery enzymes) compared to controls (2.6 ng / ml each, value-p <0.001). However, the median hepatic sound formation was 0.0 ng / mL in both groups.
We observed the super level that increased significantly in accordance with a higher child class (4.5 ng / ml, 6.9 ng / ml and 9.0 ng / ml, each child A, B, C respectively; P-value <0.001), and the median suppar concentration which is much higher in patients with ascites versus patients without ascites (8.1 ng / ml versus 5.3 ng / ml, respectively, the value of p <0.001).
Description: Urokinase (peptidolytic) (EC 3.4.21.73) is a serine protease, an inactive form (zymogen) of the serine protease plasminogen. Activation of plasmin triggers a proteolytic cascade reaction, which in turn participates in thrombolysis or extracellular matrix degradation, implicated in vascular disease and cancer-related research[1].
Description: A competitive ELISA for quantitative measurement of Human Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Urokinase in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: Quantitative sandwich ELISA for measuring Human Urokinase (UK) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Human Urokinase (UK) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Human Urokinase (UK) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: A competitive ELISA for quantitative measurement of Human Urokinase plasminogen activator in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Urokinase plasminogen activator in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Urokinase plasminogen activator in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: PLAU, a member of the peptidase family S1, is a potent plasminogen activator and is clinically used for therapy of thrombolytic disorders. PLAU specifically cleaves the Arg-|-Val bond in plasminogen to form plasmin. The protein is found in high and low molecular mass forms. Each consists of two chains, A and B. The high molecular mass form contains a long chain A. Cleavage occurs after residue 155 in the low molecular mass form to yield a short A1 chain. The protein is used in Pulmonary Embolism (PE) to initiates fibrinolysis. Structurally, PLAU contains 1 EGF-like domain and 1 kringle domain.
Significantly associated levels related to bilirubin (r = 0.48, p <0.001), hepatic venous pressure gradient (r = 0.39, p <0.001), heart index (r = 0.24, p = 0.02) and plasma volume (r = 0.33, p = 0.001), while the supar levels are significantly related to albumin (r = -0.59, p <0.001), plasma coagulation factors (R-0.39, P <0.001), pressure Arterial average (r = -0.28), p = 0.004), systemic vascular resistance (r = 0.26, p = 0.007), indocyanine green cleaning (r = -0.51, p <0.001) and galactic elimination capacity (r = -0.39, p <0.001).
Antibodies | Assay Kits | Biology Cells | cDNA | Clia Kits | Culture Cells | Devices | DNA Templates | DNA Testing | Elisa Kits | Equipments | Gels | Isotypes | Medium & Serums | NATtrol | Particles | PCR | Pcr Kits | Peptides | Recombinant Proteins | Ria Kits | RNA | Test Kits | Vector & Virus | Western Blot 
Antibodies | Assay Kits | Biology Cells | Clia Kits | Culture Cells | Devices | DNA Templates | DNA Testing | Enzymes | Equipments | Exosomes | Isotypes | Medium & Serums | NATtrol | Particles | PCR | Pcr Kits | Reagents | Recombinant Proteins | Ria Kits | RNA | Test Kits | Vector & Virus | Western Blot 
Antibodies | Assay Kits | Biology Cells | cDNA | Clia Kits | Devices | DNA | DNA Testing | Elisa Kits | Equipments | Exosomes | Gels | Isotypes | Medium & Serums | Panel | Particles | PCR | Pcr Kits | Reagents | Recombinant Proteins | Ria Kits | RNA | Test Kits | Vector & Virus | Western Blot 
Antibodies | Assay Kits | Biology Cells | cDNA | Culture Cells | Devices | DNA | DNA Templates | DNA Testing | Enzymes | Exosomes | Isotypes | Medium & Serums | NATtrol | Particles | PCR | Pcr Kits | Reagents | Recombinant Proteins | Ria Kits | RNA | Test Kits | Vector & Virus | Western Blot
No Comment